Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Research & Discovery » Proteomics & Protein Research » With Revenue Dwindling, LSBC Still Hopes to Market Chips in Early 2003

With Revenue Dwindling, LSBC Still Hopes to Market Chips in Early 2003

Feb 11, 2002
Premium

Despite cash-flow problems and the termination of its research partnership with antibody-manufacturer Biosite, Large Scale Biology still has plans to release antibody chips for use in commercial research by early 2003, LSBC CEO Bob Erwin told ProteoMonitor last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

This Time, Novavax

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Shortened Visas for Some Students

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

New York's Own Review

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Science Papers Examine Y Chromosomes of Archaic Humans, Schistosomiasis Therapeutic Targets

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
29
Featured Webinar

How to Train Your DRAGEN for Pathology Informatics

Sponsored by
Illumina

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

What's Popular?

In Proteomics & Protein Research

  1. Ionpath Expanding Sales Force, Investing in Informatics Tools Development

    Premium

  2. Ionpath Closes $18M Series B Round

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.